Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Risk/benefit profile of bevacizumab in metastatic colon cancer: a systematic review and meta-analysis.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Risk/benefit profile of bevacizumab in metastatic colon cancer: a systematic review and meta-analysis.
Risk/benefit profile of bevacizumab in metastatic colon cancer: a systematic review and meta-analysis. Dig Liver Dis. 2011 Apr; 43(4):286-94.
View in:
PubMed
subject areas
Angiogenesis Inhibitors
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Bevacizumab
Colorectal Neoplasms
Disease-Free Survival
Humans
Neoplasm Metastasis
Risk Assessment
Survival Rate
authors with profiles
Marina Chiara Garassino